• Orexo will present additional OX640 data in two oral presentations at ACAAI in Phoenix on November 13, 2026.
• Results indicate rapid achievement of clinically meaningful epinephrine levels, with long-term stability even under accelerated aging conditions.
• OX640 is a nasal epinephrine powder in clinical development for emergency anaphylaxis treatment as a needle-free alternative to epinephrine autoinjectors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.